Prolung, Inc. is a development-stage medical technology company specializing in predictive analytic, early stage lung cancer risk testing, which refer to as the ProLung Test. The Company's ProLung Test is developed to immediately assess the risk of malignancy in lung nodules found in the chest by a Computed Tomography (CT) scan. The Company's Lead Product is ProLung Test, which is designed to evaluate the risk of lung cancer in patients with lung nodules in well-controlled clinical trials. The ProLung Test includes components, such as ProLung System and ProLung Test Kit. ProLung System consists of the probe, scanner, tower, monitor, and keyboard which are all medical grade components. This component is available for sale in English, French, German, Spanish, and Italian versions. ProLung Test Kit includes six diaphoretic electrodes, one probe tip and one moistening sponge.
More about the company